196 related articles for article (PubMed ID: 25799952)
1. Inhibition of angiogenesis by selective estrogen receptor modulators through blockade of cholesterol trafficking rather than estrogen receptor antagonism.
Shim JS; Li RJ; Lv J; Head SA; Yang EJ; Liu JO
Cancer Lett; 2015 Jun; 362(1):106-15. PubMed ID: 25799952
[TBL] [Abstract][Full Text] [Related]
2. Tamoxifen Directly Inhibits Platelet Angiogenic Potential and Platelet-Mediated Metastasis.
Johnson KE; Forward JA; Tippy MD; Ceglowski JR; El-Husayni S; Kulenthirarajan R; Machlus KR; Mayer EL; Italiano JE; Battinelli EM
Arterioscler Thromb Vasc Biol; 2017 Apr; 37(4):664-674. PubMed ID: 28153880
[TBL] [Abstract][Full Text] [Related]
3. Impact of ER520, a candidate of selective estrogen receptor modulators, on in vitro cell growth, migration, invasion, angiogenesis and in vivo tumor xenograft of human breast cancer cells.
Wang L; Wang Y; Du H; Jiang Y; Tang Z; Liu H; Xiang H; Xiao H
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1247-57. PubMed ID: 26464351
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological blockade of cholesterol trafficking by cepharanthine in endothelial cells suppresses angiogenesis and tumor growth.
Lyu J; Yang EJ; Head SA; Ai N; Zhang B; Wu C; Li RJ; Liu Y; Yang C; Dang Y; Kwon HJ; Ge W; Liu JO; Shim JS
Cancer Lett; 2017 Nov; 409():91-103. PubMed ID: 28923401
[TBL] [Abstract][Full Text] [Related]
5. Selective estrogen receptor (ER) modulators differentially regulate phospholipase D catalytic activity in ER-negative breast cancer cells.
Eisen SF; Brown HA
Mol Pharmacol; 2002 Oct; 62(4):911-20. PubMed ID: 12237338
[TBL] [Abstract][Full Text] [Related]
6. Improving the efficacy of hormone therapy in breast cancer: The role of cholesterol metabolism in SERM-mediated autophagy, cell differentiation and death.
Leignadier J; Dalenc F; Poirot M; Silvente-Poirot S
Biochem Pharmacol; 2017 Nov; 144():18-28. PubMed ID: 28642035
[TBL] [Abstract][Full Text] [Related]
7. Novel SERMs based on 3-aryl-4-aryloxy-2H-chromen-2-one skeleton - A possible way to dual ERα/VEGFR-2 ligands for treatment of breast cancer.
Luo G; Li X; Zhang G; Wu C; Tang Z; Liu L; You Q; Xiang H
Eur J Med Chem; 2017 Nov; 140():252-273. PubMed ID: 28942113
[TBL] [Abstract][Full Text] [Related]
8. Detection of Endogenous Selective Estrogen Receptor Modulators such as 27-Hydroxycholesterol.
Nelson ER
Methods Mol Biol; 2016; 1366():431-443. PubMed ID: 26585155
[TBL] [Abstract][Full Text] [Related]
9. 5,6-Epoxy-cholesterols contribute to the anticancer pharmacology of tamoxifen in breast cancer cells.
Segala G; de Medina P; Iuliano L; Zerbinati C; Paillasse MR; Noguer E; Dalenc F; Payré B; Jordan VC; Record M; Silvente-Poirot S; Poirot M
Biochem Pharmacol; 2013 Jul; 86(1):175-89. PubMed ID: 23500540
[TBL] [Abstract][Full Text] [Related]
10. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer.
Jordan VC; O'Malley BW
J Clin Oncol; 2007 Dec; 25(36):5815-24. PubMed ID: 17893378
[TBL] [Abstract][Full Text] [Related]
11. Induction of p21WAF1 expression via Sp1-binding sites by tamoxifen in estrogen receptor-negative lung cancer cells.
Lee TH; Chuang LY; Hung WC
Oncogene; 2000 Aug; 19(33):3766-73. PubMed ID: 10949931
[TBL] [Abstract][Full Text] [Related]
12. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
13. Research resource: Transcriptional profiling in a cellular model of breast cancer reveals functional and mechanistic differences between clinically relevant SERM and between SERM/estrogen complexes.
Wardell SE; Kazmin D; McDonnell DP
Mol Endocrinol; 2012 Jul; 26(7):1235-48. PubMed ID: 22570330
[TBL] [Abstract][Full Text] [Related]
14. The estrogen receptor: a model for molecular medicine.
Jensen EV; Jordan VC
Clin Cancer Res; 2003 Jun; 9(6):1980-9. PubMed ID: 12796359
[TBL] [Abstract][Full Text] [Related]
15. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.
Canon J; Bryant R; Roudier M; Branstetter DG; Dougall WC
Breast Cancer Res Treat; 2012 Oct; 135(3):771-80. PubMed ID: 22926264
[TBL] [Abstract][Full Text] [Related]
16. Selective estrogen receptor modulators: a new category of compounds to extend postmenopausal women's health.
Goldstein SR
Int J Fertil Womens Med; 1999; 44(5):221-6. PubMed ID: 10569450
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
18. Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges.
Rej RK; Thomas JE; Acharyya RK; Rae JM; Wang S
J Med Chem; 2023 Jul; 66(13):8339-8381. PubMed ID: 37377342
[TBL] [Abstract][Full Text] [Related]
19. [Selective estrogen receptor modulators (SERMs) in the practice].
Nagykálnai T
Magy Onkol; 2002; 46(2):165-75. PubMed ID: 12202896
[TBL] [Abstract][Full Text] [Related]
20. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
Kijima I; Itoh T; Chen S
J Steroid Biochem Mol Biol; 2005 Dec; 97(4):360-8. PubMed ID: 16263272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
